Combined Active Treatment in Type 2 Diabetes With NASH

NCT04639414 on ClinicalTrials.gov · last registry update 2026-07-08

An unusually large phase 4: 192 participants, more than double the 75 typical for the stage. The sponsor logged completion for 31 January 2025. Primary outcome, as filed: Histological resolution of NASH without worsening of fibrosis. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: German Diabetes Center
Sponsor type: Other
Enrollment: 192
Started: 2021-03-26
Primary completion: 2025-01-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Histological resolution of NASH without worsening of fibrosis

Conditions studied

Type 2 Diabetes · Non-alcoholic Steatohepatitis (NASH) · Non-alcoholic Fatty Liver Disease (NAFLD)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.